{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:20Z","timestamp":1781643500337,"version":"3.54.5"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Capital's Funds for Health Improvement and Research","award":["Nos. 2022-1-2152, 2022-4-2156 and 2024-1-2151"],"award-info":[{"award-number":["Nos. 2022-1-2152, 2022-4-2156 and 2024-1-2151"]}]},{"name":"National Key Research and Development Program of China","award":["Nos. 2023YFF0613403"],"award-info":[{"award-number":["Nos. 2023YFF0613403"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Nos. 82070205, 81972807, 81670187, 32300655 and 82300214"],"award-info":[{"award-number":["Nos. 82070205, 81972807, 81670187, 32300655 and 82300214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["Nos. L244063 and L244025"],"award-info":[{"award-number":["Nos. L244063 and L244025"]}]},{"name":"Cultivation plan in Haidian District","award":["HP2022-19-503004"],"award-info":[{"award-number":["HP2022-19-503004"]}]},{"name":"Beijing Hospital Authority Cultivation plan","award":["PX2022046"],"award-info":[{"award-number":["PX2022046"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD19-directed chimeric antigen receptor T-cell (CAR T-cell) therapy has markedly improved the prognosis of patients with relapsed or refractory large B-cell lymphoma (R\/R LBCL). However, disease progression during the manufacturing period remains a major barrier to successful treatment. Bridging therapy (BT), defined as anti-lymphoma treatment administered between leukapheresis and lymphodepleting chemotherapy, serves two primary purposes: to prevent disease progression ensuring eligibility for CAR T-cell infusion, and to modulate the immune microenvironment to potentially enhance CAR T-cell efficacy or mitigate its toxicity. This review provides a comprehensive overview of current strategies and clinical evidence regarding BT in the context of CAR T-cell therapy. We systematically examine the efficacy and safety profiles of various BT strategies, including chemotherapy, targeted or immunotherapy agents, and radiotherapy. Furthermore, we summarize and compare findings from pivotal clinical trials and real-world studies, offering insights into the practical application and outcomes of BT in diverse clinical settings. Unresolved questions remain, including the optimal implementation of bispecific antibodies as BT regimens, the timing and duration of Bruton\u2019s tyrosine kinase inhibitors administration, the safety and efficacy of reusing polatuzumab vedotin in previously exposed patients, and the standardization of radiotherapy protocols. In conclusion, the rational selection and application of BT strategies hold promise for improving the clinical outcomes of R\/R LBCL patients undergoing CAR T-cell therapy.<\/jats:p>","DOI":"10.1007\/s00277-026-06950-0","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:11:12Z","timestamp":1774253472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for relapsed\/refractory large B-cell lymphomas"],"prefix":"10.1007","volume":"105","author":[{"given":"Jie","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jili","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"2","key":"6950_CR1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M et al (2013) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87(2):146\u2013171","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Supplement1","key":"6950_CR2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2019-129624","volume":"134","author":"MD Jain","year":"2019","unstructured":"Jain MD et al (2019) Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Blood 134(Supplement1):245\u2013245","journal-title":"Blood"},{"issue":"4","key":"6950_CR3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/hon.2965","volume":"40","author":"C Bailly","year":"2022","unstructured":"Bailly C et al (2022) Prognostic value of FDG-PET\/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma. Hematol Oncol 40(4):796\u2013800","journal-title":"Hematol Oncol"},{"issue":"1","key":"6950_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","volume":"6","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A et al (2022) Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv 6(1):321\u2013326","journal-title":"Blood Adv"},{"issue":"12","key":"6950_CR5","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1016\/S2352-3026(23)00307-1","volume":"10","author":"P Dreger","year":"2023","unstructured":"Dreger P et al (2023) CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach. Lancet Haematol 10(12):e1006\u2013e1015","journal-title":"Lancet Haematol"},{"issue":"1","key":"6950_CR6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","volume":"10","author":"M Ventin","year":"2024","unstructured":"Ventin M et al (2024) Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy: A Review. JAMA Oncol 10(1):115\u2013121","journal-title":"JAMA Oncol"},{"key":"6950_CR7","doi-asserted-by":"crossref","first-page":"706087","DOI":"10.3389\/fonc.2021.706087","volume":"11","author":"C Lyu","year":"2021","unstructured":"Lyu C et al (2021) Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory\/Relapsed DLBCL With High Tumor Bulk. Front Oncol 11:706087","journal-title":"Front Oncol"},{"issue":"6","key":"6950_CR8","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.62347\/LLXR8002","volume":"14","author":"T van Meerten","year":"2024","unstructured":"van Meerten T et al (2024) Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma. Am J Cancer Res 14(6):2905\u20132920","journal-title":"Am J Cancer Res"},{"issue":"2","key":"6950_CR9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke FL et al (2024) Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med 30(2):507\u2013518","journal-title":"Nat Med"},{"issue":"8","key":"6950_CR10","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1002\/hem3.142","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama AV et al (2024) PD-L1(+) macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy. Hemasphere 8(8):e142","journal-title":"Hemasphere"},{"issue":"12","key":"6950_CR11","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","volume":"7","author":"C Roddie","year":"2023","unstructured":"Roddie C et al (2023) Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv 7(12):2872\u20132883","journal-title":"Blood Adv"},{"key":"6950_CR12","doi-asserted-by":"crossref","first-page":"1633644","DOI":"10.3389\/fonc.2025.1633644","volume":"15","author":"PJ Ho","year":"2025","unstructured":"Ho PJ et al (2025) Real-world Australian experience with tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization. Front Oncol 15:1633644","journal-title":"Front Oncol"},{"issue":"5","key":"6950_CR13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L et al (2022) Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 19(5):342\u2013355","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"6950_CR14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I et al (2020) Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105(2):297\u2013316","journal-title":"Haematologica"},{"issue":"27","key":"6950_CR15","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ et al (2020) Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 38(27):3119\u20133128","journal-title":"J Clin Oncol"},{"issue":"1","key":"6950_CR16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ et al (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"31","key":"6950_CR17","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M et al (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32(31):3490\u20133496","journal-title":"J Clin Oncol"},{"issue":"5","key":"6950_CR18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","volume":"35","author":"GW van Imhoff","year":"2017","unstructured":"van Imhoff GW et al (2017) Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. J Clin Oncol 35(5):544\u2013551","journal-title":"J Clin Oncol"},{"issue":"2","key":"6950_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G et al (2024) Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol 42(2):205\u2013217","journal-title":"J Clin Oncol"},{"issue":"7","key":"6950_CR20","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/hem3.86","volume":"8","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G et al (2024) Efficacy and safety of bendamustine-containing bridging therapy in R\/R LBCL patients receiving CD19 CAR T-cells. Hemasphere 8(7):e86","journal-title":"Hemasphere"},{"issue":"11","key":"6950_CR21","doi-asserted-by":"crossref","first-page":"e009212","DOI":"10.1136\/jitc-2024-009212","volume":"12","author":"R Xiao","year":"2024","unstructured":"Xiao R et al (2024) Bendamustine-rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS-STING activation in diffuse large B-cell lymphoma. J Immunother Cancer 12(11):e009212","journal-title":"J Immunother Cancer"},{"issue":"12","key":"6950_CR22","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1097\/HS9.0000000000000984","volume":"7","author":"E Shumilov","year":"2023","unstructured":"Shumilov E et al (2023) CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement. Hemasphere 7(12):e984","journal-title":"Hemasphere"},{"issue":"1","key":"6950_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook MR et al (2023) Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv 7(1):32\u201339","journal-title":"Blood Adv"},{"issue":"21","key":"6950_CR24","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1182\/blood.2023020168","volume":"142","author":"JP Alderuccio","year":"2023","unstructured":"Alderuccio JP, Nayak L, Cwynarski K (2023) How I treat secondary CNS involvement by aggressive lymphomas. Blood 142(21):1771\u20131783","journal-title":"Blood"},{"issue":"5","key":"6950_CR25","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3(5):e217\u2013e227","journal-title":"Lancet Haematol"},{"issue":"10343","key":"6950_CR26","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M et al (2022) Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399(10343):2294\u20132308","journal-title":"Lancet"},{"issue":"11","key":"6950_CR27","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques P et al (2020) Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am J Hematol 95(11):1324\u20131333","journal-title":"Am J Hematol"},{"issue":"5","key":"6950_CR28","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","volume":"14","author":"MS Czuczman","year":"2008","unstructured":"Czuczman MS et al (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 14(5):1561\u20131570","journal-title":"Clin Cancer Res"},{"issue":"20","key":"6950_CR29","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","volume":"113","author":"J Hiraga","year":"2009","unstructured":"Hiraga J et al (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113(20):4885\u20134893","journal-title":"Blood"},{"issue":"4","key":"6950_CR30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3904\/kjim.2017.036","volume":"34","author":"KM Cho","year":"2019","unstructured":"Cho KM et al (2019) Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. Korean J Intern Med 34(4):885\u2013893","journal-title":"Korean J Intern Med"},{"issue":"20","key":"6950_CR31","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1002\/cncr.25253","volume":"116","author":"K Matsue","year":"2010","unstructured":"Matsue K et al (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 116(20):4769\u20134776","journal-title":"Cancer"},{"issue":"5","key":"6950_CR32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379\u2013391","journal-title":"Lancet Oncol"},{"issue":"8","key":"6950_CR33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF et al (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18(8):585\u2013608","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"6950_CR34","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3324\/haematol.2024.285255","volume":"109","author":"M Melody","year":"2024","unstructured":"Melody M, Gordon LI (2024) Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma. Haematologica 109(10):3138\u20133145","journal-title":"Haematologica"},{"issue":"10","key":"6950_CR35","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N et al (2022) T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140(10):1104\u20131118","journal-title":"Blood"},{"issue":"Supplement 1","key":"6950_CR36","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2022-162594","volume":"140","author":"G Crochet","year":"2022","unstructured":"Crochet G et al (2022) CAR T-Cell Therapy Remain Effective in Patients with Relapse\/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry. Blood 140(Supplement 1):4639\u20134641","journal-title":"Blood"},{"issue":"S3","key":"6950_CR37","doi-asserted-by":"crossref","first-page":"e44870094","DOI":"10.1002\/hon.70094_448","volume":"43","author":"HK Zieger","year":"2025","unstructured":"Zieger HK et al (2025) 448 | BISPECIFIC ANTIBODIES AS HOLDING OR BRIDGING THERAPY BEFORE CAR-T IN LARGE B-CELL LYMPHOMA. Hematol Oncol 43(S3):e44870094","journal-title":"Hematol Oncol"},{"issue":"16","key":"6950_CR38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL et al (2024) Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood 143(16):1565\u20131575","journal-title":"Blood"},{"issue":"3","key":"6950_CR39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","volume":"144","author":"G Crochet","year":"2024","unstructured":"Crochet G et al (2024) Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood 144(3):334\u2013338","journal-title":"Blood"},{"issue":"9","key":"6950_CR40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA et al (2016) Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127(9):1117\u20131127","journal-title":"Blood"},{"issue":"19","key":"6950_CR41","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J et al (2020) Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 135(19):1650\u20131660","journal-title":"Blood"},{"issue":"8","key":"6950_CR42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson A et al (2024) CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood 143(8):673\u2013684","journal-title":"Blood"},{"issue":"4","key":"6950_CR43","doi-asserted-by":"crossref","first-page":"e70310","DOI":"10.1002\/ctm2.70310","volume":"15","author":"R Shen","year":"2025","unstructured":"Shen R et al (2025) Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma: A retrospective observational study. Clin Transl Med 15(4):e70310","journal-title":"Clin Transl Med"},{"issue":"6","key":"6950_CR44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/CM9.0000000000003504","volume":"138","author":"L Wang","year":"2025","unstructured":"Wang L et al (2025) Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed\/refractory diffuse large B-cell lymphoma. Chin Med J (Engl) 138(6):748\u2013750","journal-title":"Chin Med J (Engl)"},{"key":"6950_CR45","first-page":"100902","volume":"43","author":"J Xu","year":"2025","unstructured":"Xu J et al (2025) Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis. Cancer Treat Res Commun 43:100902","journal-title":"Cancer Treat Res Commun"},{"issue":"Supplement 1","key":"6950_CR46","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2023-183034","volume":"142","author":"C Poh","year":"2023","unstructured":"Poh C et al (2023) Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory B-Cell Lymphoma: A Phase I\/II Study of Safety, Efficacy and Immune Correlative Analysis. Blood 142(Supplement 1):2129\u20132129","journal-title":"Blood"},{"issue":"7","key":"6950_CR47","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcyt.2023.03.005","volume":"25","author":"W Luo","year":"2023","unstructured":"Luo W et al (2023) Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma. Cytotherapy 25(7):739\u2013749","journal-title":"Cytotherapy"},{"issue":"2","key":"6950_CR48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","volume":"6","author":"LH Sehn","year":"2022","unstructured":"Sehn LH et al (2022) Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv 6(2):533\u2013543","journal-title":"Blood Adv"},{"issue":"13","key":"6950_CR49","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","volume":"5","author":"N Liebers","year":"2021","unstructured":"Liebers N et al (2021) Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv 5(13):2707\u20132716","journal-title":"Blood Adv"},{"issue":"9","key":"6950_CR50","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/bloodadvances.2021005953","volume":"6","author":"M Northend","year":"2022","unstructured":"Northend M et al (2022) Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed\/refractory DLBCL. Blood Adv 6(9):2920\u20132926","journal-title":"Blood Adv"},{"issue":"4","key":"6950_CR51","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA et al (2022) GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140(4):349\u2013358","journal-title":"Blood"},{"issue":"4","key":"6950_CR52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H et al (2022) Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386(4):351\u2013363","journal-title":"N Engl J Med"},{"issue":"13","key":"6950_CR53","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2009-02-205500","volume":"114","author":"D Dornan","year":"2009","unstructured":"Dornan D et al (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114(13):2721\u20132729","journal-title":"Blood"},{"issue":"2","key":"6950_CR54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.18341","volume":"199","author":"N Kawasaki","year":"2022","unstructured":"Kawasaki N et al (2022) The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. Br J Haematol 199(2):245\u2013255","journal-title":"Br J Haematol"},{"issue":"12","key":"6950_CR55","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1080\/10428194.2023.2243531","volume":"64","author":"N Kawasaki","year":"2023","unstructured":"Kawasaki N et al (2023) Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models. Leuk Lymphoma 64(12):1938\u20131948","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6950_CR56","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/10428194.2021.1986219","volume":"63","author":"J Duell","year":"2022","unstructured":"Duell J et al (2022) CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. Leuk Lymphoma 63(2):468\u2013472","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"6950_CR57","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY et al (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 27(8):1419\u20131431","journal-title":"Nat Med"},{"issue":"14","key":"6950_CR58","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M et al (2020) KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 382(14):1331\u20131342","journal-title":"N Engl J Med"},{"issue":"14","key":"6950_CR59","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-23-1962","volume":"30","author":"J Lownik","year":"2024","unstructured":"Lownik J et al (2024) Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma. Clin Cancer Res 30(14):2895\u20132904","journal-title":"Clin Cancer Res"},{"issue":"9","key":"6950_CR60","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","volume":"106","author":"J Duell","year":"2021","unstructured":"Duell J et al (2021) Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 106(9):2417\u20132426","journal-title":"Haematologica"},{"issue":"19","key":"6950_CR61","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","volume":"68","author":"HM Horton","year":"2008","unstructured":"Horton HM et al (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 68(19):8049\u20138057","journal-title":"Cancer Res"},{"issue":"6","key":"6950_CR62","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","volume":"115","author":"FT Awan","year":"2010","unstructured":"Awan FT et al (2010) CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115(6):1204\u20131213","journal-title":"Blood"},{"issue":"3","key":"6950_CR63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.2022018905","volume":"143","author":"RL Sakemura","year":"2024","unstructured":"Sakemura RL et al (2024) CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood 143(3):258\u2013271","journal-title":"Blood"},{"issue":"20","key":"6950_CR64","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/bloodadvances.2024013726","volume":"8","author":"V Camus","year":"2024","unstructured":"Camus V et al (2024) Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy. Blood Adv 8(20):5371\u20135381","journal-title":"Blood Adv"},{"issue":"1","key":"6950_CR65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-024-00706-6","volume":"13","author":"N Epperla","year":"2025","unstructured":"Epperla N et al (2025) Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Biomark Res 13(1):18","journal-title":"Biomark Res"},{"issue":"10","key":"6950_CR66","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F et al (2018) ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 131(10):1094\u20131105","journal-title":"Blood"},{"issue":"16","key":"6950_CR67","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/bloodadvances.2020002587","volume":"4","author":"PFC Bicky Thapa","year":"2020","unstructured":"Bicky Thapa PFC, Kirit M, Ardeshna M, Solh C, Carlo-Stella BS, Kahl (2020) Mehdi Hamadani, CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv 4(16):3850\u20133852","journal-title":"Blood Adv"},{"issue":"5","key":"6950_CR68","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/jha2.993","volume":"5","author":"M Hamadani","year":"2024","unstructured":"Hamadani M et al (2024) Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine. EJHaem 5(5):1110\u20131113","journal-title":"EJHaem"},{"issue":"2","key":"6950_CR69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41409-023-02148-4","volume":"59","author":"M Iqbal","year":"2024","unstructured":"Iqbal M et al (2024) Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transpl 59(2):211\u2013216","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"6950_CR70","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s13402-023-00833-6","volume":"46","author":"Z Jin","year":"2023","unstructured":"Jin Z et al (2023) Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma. Cell Oncol (Dordr) 46(4):1143\u20131157","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"6950_CR71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","volume":"43","author":"Y Isshiki","year":"2025","unstructured":"Isshiki Y et al (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell 43(1):49\u201368e9","journal-title":"Cancer Cell"},{"issue":"10","key":"6950_CR72","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","volume":"12","author":"YG Lee","year":"2022","unstructured":"Lee YG et al (2022) Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. Cancer Discov 12(10):2372\u20132391","journal-title":"Cancer Discov"},{"issue":"5","key":"6950_CR73","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2024.04.007","volume":"42","author":"J Choi","year":"2024","unstructured":"Choi J et al (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer Cell 42(5):833\u2013849e12","journal-title":"Cancer Cell"},{"issue":"13","key":"6950_CR74","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC et al (2020) Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv 4(13):2871\u20132883","journal-title":"Blood Adv"},{"issue":"7","key":"6950_CR75","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL et al (2022) Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 386(7):640\u2013654","journal-title":"N Engl J Med"},{"issue":"1","key":"6950_CR76","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","volume":"91","author":"YD Tseng","year":"2015","unstructured":"Tseng YD et al (2015) Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 91(1):223\u2013231","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"6950_CR77","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2005.09.030","volume":"64","author":"C Martens","year":"2006","unstructured":"Martens C et al (2006) Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin\u2019s lymphoma. Int J Radiat Oncol Biol Phys 64(4):1183\u20131187","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"6950_CR78","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","volume":"12","author":"D Schaue","year":"2015","unstructured":"Schaue D, McBride WH (2015) Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 12(9):527\u2013540","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"6950_CR79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.19453","volume":"205","author":"A Kuhnl","year":"2024","unstructured":"Kuhnl A et al (2024) Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK. Br J Haematol 205(2):483\u2013494","journal-title":"Br J Haematol"},{"key":"6950_CR80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","volume":"177","author":"Q Yu","year":"2022","unstructured":"Yu Q et al (2022) Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma. Radiother Oncol 177:53\u201360","journal-title":"Radiother Oncol"},{"issue":"24","key":"6950_CR81","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","volume":"8","author":"N Kostopoulos","year":"2024","unstructured":"Kostopoulos N et al (2024) Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration. Blood Adv 8(24):6308\u20136320","journal-title":"Blood Adv"},{"key":"6950_CR82","first-page":"175883592513875","volume":"17","author":"X Chen","year":"2025","unstructured":"Chen X et al (2025) Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy. Ther Adv Med Oncol 17:17588359251387534","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"6950_CR83","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S et al (2023) Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death Dis 14(10):679","journal-title":"Cell Death Dis"},{"key":"6950_CR84","doi-asserted-by":"crossref","first-page":"813832","DOI":"10.3389\/fimmu.2021.813832","volume":"12","author":"VM Qin","year":"2021","unstructured":"Qin VM et al (2021) CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors. Front Immunol 12:813832","journal-title":"Front Immunol"},{"issue":"24","key":"6950_CR85","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.21037\/atm-22-6049","volume":"10","author":"NH Wang","year":"2022","unstructured":"Wang NH et al (2022) Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Ann Transl Med 10(24):1406","journal-title":"Ann Transl Med"},{"issue":"Supplement1","key":"6950_CR86","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/blood-2019-131449","volume":"134","author":"B Imber","year":"2019","unstructured":"Imber B et al (2019) MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy. Blood 134(Supplement1):3238\u20133238","journal-title":"Blood"},{"issue":"5","key":"6950_CR87","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ et al (2019) Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys 105(5):1012\u20131021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"6950_CR88","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","volume":"108","author":"CM Wright","year":"2020","unstructured":"Wright CM et al (2020) Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. Int J Radiat Oncol Biol Phys 108(1):178\u2013188","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6950_CR89","doi-asserted-by":"crossref","first-page":"1517348","DOI":"10.3389\/fimmu.2025.1517348","volume":"16","author":"GS Manzar","year":"2025","unstructured":"Manzar GS et al (2025) Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Front Immunol 16:1517348","journal-title":"Front Immunol"},{"issue":"1","key":"6950_CR90","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ajh.27155","volume":"99","author":"O Saifi","year":"2024","unstructured":"Saifi O et al (2024) Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed\/refractory non-Hodgkin lymphoma: A multicenter consensus approach. Am J Hematol 99(1):124\u2013134","journal-title":"Am J Hematol"},{"issue":"26","key":"6950_CR91","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS et al (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"7","key":"6950_CR92","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR et al (2022) Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 386(7):629\u2013639","journal-title":"N Engl J Med"},{"issue":"10254","key":"6950_CR93","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852","journal-title":"Lancet"},{"issue":"3","key":"6950_CR94","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","volume":"10","author":"Z Ying","year":"2021","unstructured":"Ying Z et al (2021) Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China. Cancer Med 10(3):999\u20131011","journal-title":"Cancer Med"},{"issue":"1","key":"6950_CR95","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","volume":"108","author":"M Kwon","year":"2023","unstructured":"Kwon M et al (2023) Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica 108(1):110\u2013121","journal-title":"Haematologica"},{"issue":"10","key":"6950_CR96","first-page":"988e1","volume":"30","author":"R Bail\u00e9n","year":"2024","unstructured":"Bail\u00e9n R et al (2024) Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC\/GELTAMO. Transpl Cell Ther 30(10):988e1\u2013988e11","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"6950_CR97","doi-asserted-by":"crossref","first-page":"e907","DOI":"10.1097\/HS9.0000000000000907","volume":"7","author":"V B\u00fccklein","year":"2023","unstructured":"B\u00fccklein V et al (2023) Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed\/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. Hemasphere 7(8):e907","journal-title":"Hemasphere"},{"issue":"3","key":"6950_CR98","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","volume":"198","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A et al (2022) A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience. Br J Haematol 198(3):492\u2013502","journal-title":"Br J Haematol"},{"issue":"5","key":"6950_CR99","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-24-0052","volume":"5","author":"F Stella","year":"2024","unstructured":"Stella F et al (2024) A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas. Blood Cancer Discov 5(5):318\u2013330","journal-title":"Blood Cancer Discov"},{"key":"6950_CR100","doi-asserted-by":"crossref","unstructured":"Kuhnl A et al (2021) Radiotherapy Bridging in Patients With R\/R High-Grade Lymphoma Receiving CD19 CAR-T in the UK. International Journal of Radiation Oncology*Biology*Physics, 111(3, Supplement): p. S130","DOI":"10.1016\/j.ijrobp.2021.07.296"},{"issue":"5","key":"6950_CR101","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","volume":"116","author":"O Saifi","year":"2023","unstructured":"Saifi O et al (2023) Don\u2019t Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 116(5):999\u20131007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6950_CR102","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","volume":"166","author":"O Saifi","year":"2022","unstructured":"Saifi O et al (2022) Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? Radiother Oncol 166:171\u2013179","journal-title":"Radiother Oncol"},{"key":"6950_CR103","doi-asserted-by":"crossref","unstructured":"Ladbury C et al (2023) Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed\/Refractory Large B Cell Lymphoma. Cancers (Basel), 15(6)","DOI":"10.3390\/cancers15061747"},{"issue":"7","key":"6950_CR104","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamaoncol.2024.1113","volume":"10","author":"O Saifi","year":"2024","unstructured":"Saifi O et al (2024) Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma. JAMA Oncol 10(7):979\u2013981","journal-title":"JAMA Oncol"},{"issue":"2","key":"6950_CR105","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.ijrobp.2024.07.2276","volume":"120","author":"T Shimizuguchi","year":"2024","unstructured":"Shimizuguchi T et al (2024) Radiation Therapy as a Bridging Strategy in CAR-T Cell Therapy and the Impact of Tumor Control Status at CAR-T Cell Infusion. Int J Radiat Oncol Biol Phys 120(2):S207","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06950-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06950-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06950-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:41:35Z","timestamp":1781642495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06950-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":105,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6950"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06950-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"197"}}